Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of ...

New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

People who followed the MIND diet -- a combination of the Mediterranean diet and the Dietary Approaches to Stop Hypertension ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Registered dietitian Ayla Barmmer told The Post that about 15% of her patients taking GLP-1 medications have struggled to ...

Ozempic, a Type 2 diabetes medication that has gained widespread attention, is known for its appetite-suppressing properties.

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.